Literature DB >> 2711553

Prognostic significance of DNA ploidy in carcinoma of prostate.

S W Dejter1, R E Cunningham, P D Noguchi, R V Jones, J W Moul, D G McLeod, J H Lynch.   

Abstract

Flow cytometry was used to measure the DNA content in archived paraffin-embedded human prostatic cancer tissue for 69 patients with known outcomes that presented between 1975 and 1982. Of these, 51 patients had clinically localized lesions and were surgically staged prior to radical prostatectomy, while 18 patients presented with advanced Stage D2 disease. Thirty-six of 37 (97.3%) pathologic Stage B lesions were diploid. In contrast, the majority (72.2%) of patients with metastatic disease had aneuploid tumors. The average Gleason grade for aneuploid tumors was 8.2 +/- 1.98 versus 5.5 +/- 1.89 for diploid tumors (p less than 0.01). For 51 patients with clinically localized tumors, 13.9 percent of diploid tumors with a low Gleason sum (2 to 6) had extracapsular spread of tumor or regional lymph node involvement compared with 83.3 percent of aneuploid tumors with high Gleason scores (7 to 10). The addition of DNA ploidy to degree of glandular differentiation may enhance the prognostic evaluation of prostatic tumors and eventually improve our ability to select patients who are likely to benefit from radical prostatectomy.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2711553     DOI: 10.1016/0090-4295(89)90026-5

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  2 in total

1.  DNA-ploidy, G2M-fractions and prognosis of stages B and C prostate carcinoma.

Authors:  J G Müller; S Demel; M P Wirth; A Manseck; H G Frohmüller; H A Müller
Journal:  Virchows Arch       Date:  1994       Impact factor: 4.064

2.  Flow cytometric analysis of DNA ploidy and S-phase fraction from prostatic carcinomas: implications for prognosis and response to endocrine therapy.

Authors:  T Visakorpi; O P Kallioniemi; I Y Paronen; J J Isola; A I Heikkinen; T A Koivula
Journal:  Br J Cancer       Date:  1991-09       Impact factor: 7.640

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.